Condition Deep-Dives 11 min read·Updated 22 July 2026 Clinician-reviewed

Von Hippel-Lindau Disease & the Kidney

A UK Consultant Nephrologist on the renal manifestations of Von Hippel-Lindau disease (VHL) — multifocal clear cell renal cell carcinoma, complex cysts, the 3 cm intervention rule and the new belzutifan era that is delaying surgery and preserving nephrons.

  • Clinically Reviewed
  • NHS & NICE Aligned
  • UK Evidence-Based
  • Last Reviewed 22 July 2026

Professor Mohammed Mahdi Althaf

Consultant Nephrologist & Acute Physician

View Credentials

Professor Mohammed Mahdi Althaf

MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN

Consultant Nephrologist & Acute Physician · GMC 7216325

View profile →

Direct answer

VHL is autosomal dominant. 70% develop clear-cell RCC, usually multifocal and bilateral. The 3 cm rule guides intervention. Nephron-sparing partial nephrectomy or ablation is preferred over radical surgery. Belzutifan (NICE TA940) is now first-line systemic therapy. Annual MRI + multi-system surveillance from teenage years.

Key recommendation: Autosomal dominant; 70% develop ccRCC by age 60.

Quick answer

✓ Best choices

  • Vegetables, lower-potassium fruit and whole grains
  • Sensible portions of fish, eggs, chicken or tofu
  • Olive oil and unsalted nuts in small amounts

✓ Foods to limit

  • Added salt and ultra-processed foods
  • Phosphate additives in processed meats and ready meals
  • Sugary and energy drinks

Key takeaway

VHL is autosomal dominant. 70% develop clear-cell RCC, usually multifocal and bilateral. The 3 cm rule guides intervention. Nephron-sparing partial nephrectomy or ablation is preferred over radical surgery. Belzutifan (NICE TA940) is now first-line systemic therapy. Annual MRI + multi-system surveillance from teenage years.

Who should be cautious

People on dialysis, post-transplant, pregnant or breastfeeding, or taking prescription medication — confirm with your renal team before changes.

Von Hippel-Lindau Disease & the Kidney

Genetics & disease overview

Genetics

  • Autosomal dominant
  • VHL tumour suppressor gene (chromosome 3p25)
  • Loss of VHL → stabilisation of HIF-1α / HIF-2α → constitutive hypoxia-response signalling → tumour formation
  • 20% de novo mutations
  • Penetrance ~90% by age 65
  • NHS National Genomic Test Directory R210

Classification

  • Type 1: low pheochromocytoma risk (most cases)
  • Type 2A: pheochromocytoma + RCC + haemangioblastoma
  • Type 2B: pheochromocytoma + RCC + haemangioblastoma + high cancer burden
  • Type 2C: isolated pheochromocytoma

Kidney-specific Features

  • Multiple bilateral renal cysts (often Bosniak II–III)
  • Clear-cell renal cell carcinoma — multifocal, bilateral, mean age at first tumour ~39
  • Lifetime ccRCC risk: 50–70%
  • Distant metastases possible (lung, bone, brain) — lifelong cancer survivorship

Other Vhl Features

  • CNS haemangioblastomas (cerebellum, brainstem, spinal cord)
  • Retinal haemangioblastomas (cause of blindness if untreated)
  • Pheochromocytoma / paraganglioma
  • Pancreatic neuroendocrine tumours + cysts
  • Endolymphatic sac tumours (hearing loss)
  • Epididymal / broad ligament cystadenomas

Surveillance protocol (UK NHS)

From Childhood

  • Age 1: ophthalmology baseline; annual review
  • Age 2: audiology
  • Age 5: annual urinary / plasma metanephrines
  • Age 8: clinical review for neurological signs
  • Age 11: baseline brain & spine MRI

FROM AGE 16 (or earlier if symptomatic):

  • Annual MRI abdomen (kidneys, pancreas, adrenals) — gadolinium-enhanced
  • Annual U&E, eGFR, urine ACR, BP
  • Continue metanephrines annually
  • Ophthalmology annually
  • Audiology every 2–3 years
  • Brain/spine MRI every 2–3 years

Pre-operative Planning

  • Always screen for pheochromocytoma before any surgical intervention
  • 24-h urinary metanephrines + plasma metanephrines
  • Treat any pheochromocytoma first (alpha then beta blockade)

Surveillance-driven Intervention

  • Use MRI to track each individual tumour (volume, growth rate)
  • Document a 'tumour map' to plan future surgery and avoid wholesale nephrectomy

Treatment & long-term care

The 3 Cm Rule

  • Most ccRCCs < 3 cm grow slowly and metastasise rarely
  • Active surveillance is safe for tumours < 3 cm in VHL
  • Intervene when the LARGEST tumour reaches 3 cm
  • Continue surveillance of other small tumours

INTERVENTION OPTIONS (nephron-sparing first):

  • PARTIAL NEPHRECTOMY (open / robotic / laparoscopic) — gold standard
  • PERCUTANEOUS ABLATION (cryoablation, RFA, microwave) — increasingly used for small (<4 cm) cortical lesions
  • RADICAL NEPHRECTOMY — last resort; preserves no nephrons
  • Repeated interventions are expected over a lifetime — careful surgical planning preserves long-term kidney function

BELZUTIFAN (Welireg, NICE TA940 — 2024):

  • Oral HIF-2α inhibitor 120 mg/day
  • Approved for VHL-associated RCC, CNS haemangioblastoma, pancreatic NET not requiring immediate surgery
  • LITESPARK-004 trial: 49% RCC response rate; durable tumour shrinkage
  • Side effects: anaemia (very common — often needs erythropoietin-stimulating agent), hypoxia (especially exercise), fatigue, nausea
  • Pregnancy contraindicated (teratogen)
  • Delivered through NHS specialised commissioning centres (e.g. Royal Free, Birmingham, Manchester)

Metastatic Disease

  • Standard mRCC therapies (IO-TKI combinations) used; VHL-specific data limited
  • Belzutifan is FDA/NICE approved for metastatic ccRCC in VHL

Transplantation

  • Bilateral nephrectomy + transplant occasionally needed in late disease
  • Transplant outcomes are good; immunosuppression does not appear to drive new VHL tumours, but ongoing extra-renal cancer surveillance continues
  • Belzutifan can be considered post-transplant — specialist decision

Family & Genetic Counselling

  • 50% transmission per child
  • Predictive testing offered from age 5 (allows surveillance to start at right age in carriers and stop in non-carriers)
  • Pre-implantation genetic diagnosis available

UK PATHWAY: care should be delivered in a Highly Specialised Service VHL clinic (NHS England commissioning) with renal, urology, neurosurgery, endocrinology, ophthalmology, ENT and clinical genetics input.

Renal Cell Carcinoma (Kidney Cancer)
Related reading: Renal Cell Carcinoma (Kidney Cancer).

Key practical tips

Designed for quick scanning — what to order, what to avoid, sensible portions, common mistakes.

  • Cook from scratch when you can
  • Read sodium labels (≤ 0.3 g per 100 g is low)
  • Take any concerns to your GP or renal team early

Clinical guidance

TL;DR summary

VHL is autosomal dominant. 70% develop clear-cell RCC, usually multifocal and bilateral. The 3 cm rule guides intervention. Nephron-sparing partial nephrectomy or ablation is preferred over radical surgery. Belzutifan (NICE TA940) is now first-line systemic therapy. Annual MRI + multi-system surveillance from teenage years.

Key takeaways
  • Autosomal dominant; 70% develop ccRCC by age 60.
  • 3 cm rule: observe < 3 cm, intervene at 3 cm.
  • Always nephron-sparing — preserve eGFR for life.
  • Belzutifan (NICE TA940) shrinks tumours and delays surgery.
  • Annual MRI + ophthalmology + metanephrines surveillance.
Kidney Diet & Nutrition Considerations

Diet is one of the most powerful tools you have to look after your kidneys. UK renal guidance points to a Mediterranean-style, reduced-salt pattern: plenty of vegetables, lower-potassium fruit, whole grains, sensible protein, beans and pulses in moderation, oily fish and olive oil. Personal targets — for potassium, phosphate, protein and fluid — should be set by your renal team based on your bloods.

Foods to prioritise

  • Vegetables, lower-potassium fruit and whole grains
  • Sensible portions of fish, eggs, chicken or tofu
  • Olive oil and unsalted nuts in small amounts

Foods to limit

  • Added salt and ultra-processed foods
  • Phosphate additives in processed meats and ready meals
  • Sugary and energy drinks

Potassium, phosphate and protein needs vary between individuals — please confirm personal targets with your renal team or dietitian. Browse the Kidney Diet Hub for more guides in this cluster.

Frequently asked questions

What kidney problems occur in VHL?

Von Hippel-Lindau (VHL) is an autosomal dominant cancer predisposition syndrome. Roughly 70% of VHL patients develop clear-cell renal cell carcinoma (ccRCC) by age 60, usually multifocal and bilateral. Renal cysts (often complex) are very common. Pheochromocytoma, retinal and CNS haemangioblastomas, pancreatic neuroendocrine tumours, endolymphatic sac tumours and epididymal cysts complete the syndrome.

When are kidney tumours treated?

The classical 'VHL 3 cm rule': observe tumours < 3 cm, intervene (nephron-sparing partial nephrectomy or ablation) when the largest tumour reaches 3 cm. This balances cancer control against the harms of repeated surgery in patients destined to develop further tumours. Belzutifan (HIF-2α inhibitor) is NICE-approved (TA940) and is transforming care by shrinking VHL tumours and delaying surgery.

How is surveillance done?

UK practice (NHS England specialised commissioning / VHL UK): annual MRI of the abdomen from age 16 (or earlier if symptomatic), annual urinary/plasma metanephrines from age 5 for pheochromocytoma screen, annual ophthalmology, brain/spine MRI every 2–3 years, audiology for endolymphatic sac tumours, and genetic counselling for the whole family.

What is belzutifan and who gets it?

Belzutifan (Welireg) is an oral HIF-2α inhibitor — it blocks the downstream pathway that VHL loss-of-function activates. NICE TA940 (2024) approved it for adults with VHL-associated RCC, CNS haemangioblastoma or pancreatic neuroendocrine tumours not requiring immediate surgery. It can produce durable tumour shrinkage and significantly delay surgery. Side effects: anaemia (very common), hypoxia, fatigue. Delivered through NHS specialised commissioning centres.

What foods are good for kidney health?

A Mediterranean-style, mostly plant-based, reduced-salt diet is the most consistent evidence-based pattern for kidney health. Build meals around vegetables, lower-potassium fruit, whole grains, fish, eggs or tofu, beans and pulses in moderation, and olive oil.

Nutritional challenges in kidney disease

Many people living with kidney disease have to limit foods because of potassium, phosphate, diabetes, dialysis, appetite changes or simply the time it takes to cook from scratch every day. That can make it harder to keep daily nutrition balanced — particularly for vitamins and minerals that food alone may not fully cover.

Kidney Vitality is a UK-formulated daily nutritional support product designed by Consultant Nephrologist Professor Mohammed Mahdi Althaf with renal nutrition in mind from the start. It keeps doses moderate, leaves out added potassium, phosphate and magnesium, and avoids megadose vitamin A — sitting alongside a kidney-friendly diet, not replacing it.

Why Kidney Vitality fits this need

Built around UK guidance

Aligned with NICE TA940 belzutifan, NHS England Highly Specialised Service for VHL, NHS Genomic Test Directory R210 and the international VHL surveillance consensus.

Designed by a UK Consultant Nephrologist

Formulated and reviewed by Professor Mohammed Mahdi Althaf (GMC 7216325).

Nephron-sparing first

Practical UK guidance prioritising belzutifan, partial nephrectomy and ablation over radical surgery to preserve lifelong kidney function.

Designed by a UK Consultant Nephrologist

Ready to support your kidney health?

If you have been researching kidney health, supplements, CKD nutrition or kidney-friendly living, Kidney Vitality was developed specifically around those principles by Professor Mohammed Mahdi Althaf (GMC 7216325). Nephrologist Developed Daily Multivitamin.

  • No Added Potassium
  • No Added Magnesium
  • No Added Phosphorus
  • No Added Iron
  • One capsule daily
  • UK GMP — BRCGS, NSF GMP, Halal
Subscribe & Save — £20.39/monthCheck your current multivitamin

✓ Free UK tracked delivery  ·  ✓ Delivered every 30 days  ·  ✓ Pause or cancel anytime  ·  ✓ Never run out

ComparisonKidney VitalityTypical high-street multivitamin
Added potassiumNoneOften included
Added phosphateNoneOften included (E338–E452)
Vitamin A (retinol)No megadoseOften high-dose retinol
Kidney-focused formulationYesNo — general population
Consultant Nephrologist involvementYes (GMC 7216325)No
UK GMP manufacturedYes (BRCGS, NSF GMP)Varies

Food supplement. Not a medicine and not a treatment for kidney disease. Speak with your GP, pharmacist or renal team before starting any new supplement, especially in advanced CKD, on dialysis, post-transplant, pregnant or breastfeeding.

Clinical reviewer

Professor Mohammed Mahdi Althaf

Consultant Nephrologist

Acute Physician

GMC 7216325

View Full Biography

Professor Mohammed Mahdi Althaf is a UK Consultant Nephrologist and Acute Physician with a special interest in chronic kidney disease, AKI prevention and renal nutrition. He combines hospital practice with patient education and clinical guidance review.

View professional profile →
View Credentials
  • MD
  • MSc
  • PgDip (Clin Ed)
  • FRCP
  • FHEA
  • FASN

About this article

Written for UK patients and based on:

  • NICE guidance
  • NHS resources
  • British Dietetic Association guidance
  • Kidney Care UK resources
View methodology

Each article is researched against current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO and KDOQI international guidelines, and the British Dietetic Association Renal Nutrition Group. Drafts are written by the Kidney Vitality editorial team and reviewed by a UK Consultant Nephrologist before publication. Content is reviewed on a rolling basis and updated when guidance changes.

Editorial standards

  • Clinically reviewed
  • NHS-aligned
  • NICE-aligned
  • Evidence-based
  • Reviewed before publication
View full editorial process

Every article is researched and written by the Kidney Vitality editorial team using current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO/KDOQI international guidelines, and British Dietetic Association renal nutrition guidance. Drafts are reviewed for clinical accuracy by Professor Mohammed Mahdi Althaf, MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN (Consultant Nephrologist & Acute Physician, GMC 7216325) before publication. Content is updated when UK guidance changes.

References (4)View Sources
  1. NICE NG203: Chronic kidney disease — assessment and management
  2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
  3. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update
  4. British Dietetic Association — Renal Nutrition Group

Medical disclaimer

This content is educational only and does not replace personalised medical advice.

Read full disclaimer

This page is general information, not personal medical advice. If you have chronic kidney disease, are on dialysis, have had a kidney transplant, are pregnant or breastfeeding, or take prescription medication, please confirm any supplement with your GP, pharmacist or renal team before starting.

← Back to all guides